Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04000243
Other study ID # RAC-M
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2019
Est. completion date December 31, 2020

Study information

Verified date February 2023
Source Hospital Clinic of Barcelona
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Helicobacter pylori (Hp) is the major cause of gastritis and gastritis-associated diseases. Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature correlates with negative Hp status with a sensitivity and negative predictive value (NPV) higher than 90% in Asian countries. In a recent study carried out in our hospital, it has been shown that the presence of RAC pattern in the lesser gastric curvature, evaluated with high definition endoscopy, can accurately identify patients without Hp. The aim of this study is to confirm the validity of the endoscopic diagnosis of Hp infection in the West by means of the RAC pattern in a multicenter prospective study and to evaluate interobserver variability before establishing its applicability in clinical practice.


Description:

We designed a prospective study including patients who will undergo upper gastrointestinal endoscopy from July 2019 to June 2020 at the Endoscopy Unit of Hospital Clinic of Barcelona. The Ethics Committee of Hospital Clinic of Barcelona approved the study. Upper gastrointestinal endoscopies will be performed with high definition endoscopes (Olympus, Germany) without magnification by three endoscopists. One of the endoscopists is considered as an expert with more than 20 years of experience and prior training in Japanese centers. All the examinations will be performed with sedation controlled by an anesthesiologist. After the routine examination of the esophagus, stomach, and duodenum, close observation will be carried out at the distal part of the lesser curvature and pictures will be taken. The Olympus system will be used for image storing and text reporting. The presence of a regular or irregular arrangement of collecting venules will be evaluated in real time during gastric exploration in the lower part of the lesser curvature of the gastric body with good insufflation, close to the incisura angularis. If minute red points were visible regularly and homogenously, the finding will be scored as RAC positive (RAC+). If this finding was absent or there was a patchy distribution at the site of close observation, it will be defined as RAC negative (RAC-). The following baseline characteristics will be collected: age, sex, antibiotics, proton-pump inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), antithrombotic or anticoagulant use in the last two weeks, history of Hp eradication and detection of significant endoscopic findings (erosive duodenitis, non-erosive duodenitis, duodenal ulcer, erosive gastritis, gastric ulcer and signs of atrophic gastritis or intestinal metaplasia). Hp infection status will be determined by mucosal biopsies. We will perform 5 samples for histological study according to Sydney criteria (2 in antrum, 1 in incisura angularis and 2 in gastric body); or 2 biopsies (1 in antrum and 1 in gastric body) for histology and immunohistochemical study for Hp. Patients were classified as Hp positive if one of these two tests are positive. For the histological study, samples will be fixed in formalin and stained with hematoxylin and eosin for the evaluation of gastritis and with Giemsa for Hp status. The immunohistochemical study will be carried out systematically in the case of a negative histological study for Hp. The pathologist has access to the endoscopic diagnosis but not to RAC status. Statistical analysis The quantitative variables will be described by the mean and the standard deviation, while the qualitative variables by proportion. The sensitivity, specificity, positive predictive value (PPV), NPV and accuracy of RAC for the diagnosis of uninfected Hp patients will be calculated. 95% confidence interval will be calculated by using standard formula. Comparisons will be done using Chi-square test for categorical variables and t test for continuous variables. In addition, a multivariate logistic regression analysis will be carried out to assess the existence of predictive factors of RAC and the odds ratio (OR) was calculated to indicate the associated risk. P <0 .05 will be considered statistically significant. All statistical analyses will be performed using the SPSS, version 23 (SPSS Inc., Chicago, USA).


Recruitment information / eligibility

Status Completed
Enrollment 164
Est. completion date December 31, 2020
Est. primary completion date July 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients older than 18 years who have an upper gastrointestinal endoscopy Exclusion Criteria: - Taking antibiotics in the last 4 weeks - Presence of alimentary or hematic remains that prevent the correct visualization of the mucosa - Bleeding from the upper gastrointestinal tract - History of portal hypertensive gastropathy or lymphoma - History of partial or total gastrectomy - Refusal to participate

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Endoscopic diagnosis of Hp
Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature

Locations

Country Name City State
Spain Hospital Clinic of Barcelona Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Hospital Clinic of Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance characteristics of a regular pattern of collecting venules (RAC) for the diagnosis of infection by Helicobacter pylori Number of patients with RAC / no RAC and infection by Helicobacter pylori one year
Secondary Interobserver variability for the diagnosis of RAC Agreement among different endoscopists regarding the diagnosis of RAC in the pictures obtained and saved during the gastroscopies.
The agreement will be evaluated by Cohen's kappa coefficient
one year
Secondary Accuracy of RAC in patients treated with proton pump inhibitors Number of cases with RAC / no RAC and infection by Helicobacter pylori in the subgroup of patients treated with proton pump inhibitors one year
See also
  Status Clinical Trial Phase
Recruiting NCT05061732 - Helicobacter Pylori Eradication and Follow-up Phase 4
Completed NCT03779074 - Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies Phase 3
Completed NCT06076681 - A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Phase 1/Phase 2
Recruiting NCT05329636 - Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy Phase 1/Phase 2
Recruiting NCT05065138 - Comparison of Helicobacter Pylori Eradication Effect Before and After Training of Gastroenterologists N/A
Completed NCT05049902 - Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication Phase 4
Not yet recruiting NCT06200779 - Tailored vs. Empirical Helicobacter Pylori Infection Treatment Phase 4
Not yet recruiting NCT06037122 - Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
Completed NCT04617613 - Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait Phase 4
Completed NCT02873247 - Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori
Withdrawn NCT02552641 - Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Phase 4
Completed NCT02557932 - Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication Phase 3
Recruiting NCT02249546 - Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Phase 4
Completed NCT01933659 - Anti-H. Pylori Effect of Deep See Water Phase 3
Unknown status NCT01464060 - 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Phase 4
Completed NCT00841490 - Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults N/A
Recruiting NCT05728424 - One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL Phase 3
Recruiting NCT05549115 - Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection N/A
Recruiting NCT05997433 - Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori(SHARE2302) N/A
Completed NCT04708405 - The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation